Relapsing Forms of Multiple Sclerosis Clinical Trial
Official title:
A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules
The primary objective of this study is to evaluate the effect of symptomatic therapies on
gastrointestinal (GI)-related events reported by participants with relapsing forms of
multiple sclerosis (MS) initiating therapy with dimethyl fumarate (DMF) in the clinical
practice setting.
The secondary objectives of this study are as follows:
- To evaluate GI-related events requiring symptomatic therapy and the role of those
therapies over time in participants with relapsing forms of MS initiating therapy with
DMF in the clinical practice setting.
- To evaluate GI-related events that lead to DMF discontinuation after the use of
symptomatic therapy in participants with relapsing forms of MS initiating therapy with
DMF in the clinical practice setting.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01201356 -
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
| Suspended |
NCT04909502 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05083923 -
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 | |
| Completed |
NCT02230969 -
Plegridy Observational Program
|
||
| Withdrawn |
NCT02428218 -
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
| Completed |
NCT04676555 -
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
|
||
| Recruiting |
NCT05798520 -
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT00424788 -
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
|
Phase 0 | |
| Recruiting |
NCT06251986 -
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
|
||
| Completed |
NCT02097849 -
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
|
Phase 2 | |
| Completed |
NCT01903291 -
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
|
N/A | |
| Completed |
NCT01216072 -
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 |